Dyne Therapeutics IncDYN
ASignal's systematic analysis rates DYN as Neutral.
Reflects the latest available analysis · analyzed Aug 29, 2026
The case on DYN
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $898.48M in total cash
- Low debt-to-equity ratio of 0.33x indicating conservative leverage
- High current and quick ratios (12.02x and 11.52x) signaling strong liquidity
- MACD histogram showing contraction, potentially nearing oversold reversal
- MACD below signal line with negative histogram, indicating bearish momentum
- Negative price momentum (-0.0413) and price below 20-day SMA
- Negative free cash flow (-$317.14M) and operating cash flow (-$477.82M)
- Negative return on equity (-81.57%) and return on assets (-38.96%)
- Forward P/E of -7.50x and EV/EBITDA of -7.87x indicating unprofitability
- No Reddit mentions, suggesting lack of retail investor interest
See the full verdict on DYN
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes DYN
Most investors never get a second opinion, let alone several. ASignal runs DYN past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.